Article: [Real-World Efficacy and Safety of China-Made Flumatinib Mesylate in the Treatment of Chronic Myeloid Leukemia in Chronic Phase].
Zhongguo shi yan xue ye xue za zhi
2024 Volume 32, Issue 1, Page(s) 14–19
Abstract: Objective: To evaluate the efficacy and safty of China-made flumatinib mesylate in the treatment of chronic myeloid leukemia in chronic phase (CML-CP).: Methods: 42 CML-CP patients treated with Chinese produced flumatinib (oral, 600 mg, 1/d) were ... ...
Abstract | Objective: To evaluate the efficacy and safty of China-made flumatinib mesylate in the treatment of chronic myeloid leukemia in chronic phase (CML-CP). Methods: 42 CML-CP patients treated with Chinese produced flumatinib (oral, 600 mg, 1/d) were included in the study, including 14 newly diagnosed patients and 28 patients underwent conversion therapy. The hematological, cytogenetic and molecular response and safety were observed and evaluated after 3, 6 and 12 months of treatment. Results: 35 patients were treated for more than 3 months, among which 31 patients were treated for more than 6 months and 17 patients were treated for more than 12 months. After 3 months of treatment, 33 patients underwent hematological, cytogenetic and molecular examination. Of these, 32 patients achieved complete hematological response (CHR), 13 patients achieved complete cytogenetic response (CCyR), 20 patients showed BCR-ABL Conclusion: In the real world, China-made flumatinib mesylate has a positive short-term efficacy and reliable safety in the treatment of CML-CP patients, whether as first-line treatment or second- and third-line conversion therapy. |
---|---|
MeSH term(s) | Humans ; Imatinib Mesylate/therapeutic use ; Treatment Outcome ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy ; Protein Kinase Inhibitors/therapeutic use ; Anemia ; Thrombocytopenia ; China ; Mesylates/therapeutic use ; Antineoplastic Agents/therapeutic use ; Fusion Proteins, bcr-abl/genetics |
Chemical Substances | Imatinib Mesylate (8A1O1M485B) ; Protein Kinase Inhibitors ; Mesylates ; Antineoplastic Agents ; Fusion Proteins, bcr-abl (EC 2.7.10.2) |
Language | Chinese |
Publishing date | 2024-02-23 |
Publishing country | China |
Document type | English Abstract ; Journal Article |
ZDB-ID | 2404306-0 |
ISSN | 1009-2137 |
ISSN | 1009-2137 |
DOI | 10.19746/j.cnki.issn.1009-2137.2024.01.004 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 6603: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.